Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. - Wikidata - wikimedia - TriplyDB

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice.

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice.

http://www.wikidata.org/entity/Q27865234

about

A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1 Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1 Nutritional Signaling via Free Fatty Acid Receptors DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-Cells dysfunction in db/db mice AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents GPR40 agonist ameliorates liver X receptor-induced lipid accumulation in liver by activating AMPK pathway Progression of diet-induced diabetes in C57BL6J mice involves functional dissociation of Ca2(+) channels from secretory vesicles.GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.Perinatal exposure to bisphenol-a and the development of metabolic syndrome in CD-1 mice.Variation in the FFAR1 gene modifies BMI, body composition and beta-cell function in overweight subjects: an exploratory analysis Lipid receptors and islet function: therapeutic implications?The year in G protein-coupled receptor research.A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells Glucose metabolism in pigs expressing human genes under an insulin promoter.Differential Gene Expression in GPR40-Overexpressing Pancreatic β-cells Treated with Linoleic Acid.CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.WldS enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis Novel Agents for the Treatment of Type 2 Diabetes.Endogenous Ligand for GPR120, Docosahexaenoic Acid, Exerts Benign Metabolic Effects on the Skeletal Muscles via AMP-activated Protein Kinase Pathway.Pancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational Analysis Elevated nocturnal NEFA are an early signal for hyperinsulinaemic compensation during diet-induced insulin resistance in dogs.Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor GPR40 modulators: new kid on the block Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes.Gustducin couples fatty acid receptors to GLP-1 release in colon.GPR40: good cop, bad cop?Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems.Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets.Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease.Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.Fasiglifam as a new potential treatment option for patients with type 2 diabetes.Potential role of skeletal muscle glucose metabolism on the regulation of insulin secretion.Therapeutic role and ligands of medium- to long-chain Fatty Acid receptors.Treatment of type 2 diabetes by free Fatty Acid receptor agonists.The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism.

P2860

Q24338456-0693B61F-5FDA-4B86-B5A2-BC6FEE5D9E58 Q24629432-2FCFEBD7-E766-4DDF-AEFF-38F7F91FEE7C Q26749828-F4A148F7-7D91-40BD-BCEB-9C231772FF59 Q28533802-9B1B00E3-59BD-4809-AD3D-232CFF039F3C Q28743026-5D3C6631-DF09-4E6C-A329-0097E200568E Q28834044-3527D0E6-449A-4690-A208-0A16D11A286D Q33530805-F828A6C6-34B7-4D20-97E6-A53BBCD306A3 Q33718965-4FA07B35-63C5-44EE-A2AE-F5797A73FA7A Q33874480-288487DD-999C-406E-AF40-9E2B93F62555 Q33892691-ADC6EC60-7A9F-4B15-876B-696E65260355 Q33930824-3ED2C532-D67D-478B-B3C3-639B91E99B3C Q34088801-A605A4CD-908B-4C28-8294-53002ADA2C81 Q34441309-8D48C04D-9416-4A12-8C58-DAFCCB633C20 Q34570823-C88A0608-2D4E-4BC9-B9AF-79D1B8EFD5DE Q35085119-B9B12B62-22F4-4232-BBD0-29AC51036BBE Q35127471-82A8E644-C7BE-470C-8068-9FEC81B654E7 Q35130696-6B882D84-18D1-48A6-A03C-05F5EB0F0837 Q35561063-344C5AF3-2404-45A9-8365-333404508DC2 Q35910421-9EC7A5FF-7E03-43C3-A920-1E1C9A4BD882 Q35953181-19BF32A4-4400-4693-ABA9-AEB27306D63A Q36006492-013C0AAF-4EA8-4128-AA9B-9C307A3DF948 Q36113667-3C7FBA2C-C22A-43AB-807E-E5BF582B380B Q36165684-453EC0FF-6239-4BF4-8F6B-BD96A321E9D5 Q36327956-345CDB25-0846-414C-B2EB-33971BC71D52 Q36335625-8E0EBB19-2C05-4D01-B442-A3069C5A5C1C Q36560325-1D16FE0F-99C9-46C7-B312-3A7A65FBE1D2 Q36560412-B6FD1478-70E5-4AF9-BC0D-5092D268B1F8 Q36699764-684C2E44-E4B7-4DA8-8505-D768686029E9 Q37163504-72CBE5C4-56A1-4DCA-A44B-A03A8AC35DCE Q37237145-240C266A-DFED-4F97-BA4A-89CD8E618B9C Q37253051-E6A2126B-D505-4AB9-A385-9577D96FDD86 Q37400740-D7F63514-C260-4AD4-B134-693BDA19935E Q37810292-09654B17-EEBD-435B-946B-EF5F6598CE50 Q38067511-71DE062E-8303-4EAE-925F-A819C46A67B0 Q38123792-F76F31BE-15D0-4298-846D-B6979BBAB339 Q38160275-FBFC3DF9-119B-45F0-AD0E-C3BA77E6DF49 Q38195143-7CF39F0F-6B22-48FB-BC55-30B35BF5196E Q38219404-00540C9A-9709-4B88-B092-BF723CE6298B Q38249182-C164B123-3323-4FBD-A37B-BE2C76D5374F Q38259563-9B6A3887-AA7B-4933-A02E-E83408805340

P2860

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice.

http://www.wikidata.org/entity/Q27865234

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@ast

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@en

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@nl

type

label

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@ast

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@en

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@nl

altLabel

Overexpression of GPR40 in pan ...... ce in normal and diabetic mice

@en

prefLabel

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@ast

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@en

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@nl

P1433

Q27865234-1719DDBA-34A4-45C7-803C-E5A1A39EF791

P1476

Q27865234-A2F7DAE9-9BB0-4D8E-BBB9-14109CD96E90

P2093

Q27865234-11BEE732-FE50-42C2-90F4-02E75CC9C5B7

Q27865234-120F471B-B73A-4D86-B146-4531BEA57583

Q27865234-2239D1B7-7140-4AAB-B090-E4746C097784

Q27865234-2AA3DD85-7950-4D99-8628-AB23503A6987

Q27865234-41191BAE-E716-4973-8336-EC336655A01E

Q27865234-686D8235-C070-4D19-9F7B-692B5D4AD2EE

Q27865234-72CC5795-6673-485F-B062-8FB7EA5DD56B

Q27865234-7529A90C-600C-4E4D-95AA-98608987B72E

Q27865234-77D4AD55-BAA2-4264-AC46-4574F71271B1

Q27865234-B3A54BC5-0CF3-44BC-85F0-993F44553F3D

P2860

Q27865234-02CDC0E5-4B82-46BF-8DD3-0D96101919BD

Q27865234-0C6658E0-2F4B-4E3C-89D8-77DE59BAD570

Q27865234-104EE753-E1D1-4C4D-8F50-EDFEF40C42A1

Q27865234-22DFE8BF-BBC7-437C-9C8A-46DD02D08222

Q27865234-2A4ECCBA-2D93-4F20-8948-D78211394D9B

Q27865234-340CED5D-95F7-49AA-8E0C-336E6F48BC93

Q27865234-39961B14-ADD6-45A0-B163-B1C12B1EC62D

Q27865234-3AF5C9F7-497B-46A3-B05C-4ED7B6F4EAF6

Q27865234-452ABF2E-CEE1-4173-9F34-0974577CC912

Q27865234-4720988F-95A8-4AD5-8BFA-273C3AA7FBBD

P304

Q27865234-148793E4-CB8D-4F79-9CEF-DDFC184D7558

P31

Q27865234-CD7BD3D0-D424-4DF4-852A-76BDF5F8F2E8

P3181

Q27865234-8A95186A-A1DC-47E4-AF63-814F6744ABAC

P356

Q27865234-4438A9A9-5FF1-4154-991F-3F00AD5A2AE0

P407

Q27865234-97FC83F9-57F7-4228-AB0B-4D4E3D81C7C9

P433

Q27865234-A18A5EFE-BBB4-4141-B794-F04839E551CD

P478

Q27865234-65C52BD6-AB0B-4FC6-AD4B-C96268F837C8

P577

Q27865234-BC951025-5B94-40DB-B2BC-0311BB3929AF

P5875

Q27865234-E331BE34-880D-4FD0-ADA2-2A59424D28C5

P698

Q27865234-2430E7D5-158B-4C7C-8868-627929E5F0D5

P921

Q27865234-030BC4C5-7AE2-4D93-80BB-744EE67262F4

Q27865234-DD17585C-CD39-4F38-B5DE-48D547DFF603

Q27865234-E49A7D9B-58C2-4ED5-9BA8-719144E2B07F

Q27865234-deaf40e9-86cf-40de-8f01-d8aedc3da21f

P932

Q27865234-6D675595-FEF5-412C-8C21-E152224C962F

P3181

P356

P1433

P1476

Overexpression of GPR40 in pan ...... e in normal and diabetic mice.

@en

P2093

Hideyuki Tanaka

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Odaka

http://www.w3.org/2001/XMLSchema#string

Kae Nagasumi

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Ogi

http://www.w3.org/2001/XMLSchema#string

Kimihiko Iwachidow

http://www.w3.org/2001/XMLSchema#string

Koji Takeuchi

http://www.w3.org/2001/XMLSchema#string

Kozo Shimakawa

http://www.w3.org/2001/XMLSchema#string

Mitsugu Nakata

http://www.w3.org/2001/XMLSchema#string

Ritsuko Esaki

http://www.w3.org/2001/XMLSchema#string

Shigehisa Taketomi

http://www.w3.org/2001/XMLSchema#string

P2860

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.

A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release.

Role of GPR40 in fatty acid action on the beta cell line INS-1E.

GPR40 gene expression in human pancreas and insulinoma.

A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo.

Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40.

GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo.

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

P304

1067-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1905219

http://www.w3.org/2001/XMLSchema#string

P356

10.2337/DB08-1233

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24376361

http://www.w3.org/2001/XMLSchema#string

P698

19401434

http://www.w3.org/2001/XMLSchema#string

P921

P932

2671040

http://www.w3.org/2001/XMLSchema#string